Biocure Technology Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CURE.CN research report →
Companywww.biocuretech.com
Biocure Technology Inc. , together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions.
- CEO
- Yee Sing Cheng
- IPO
- 2009
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $408.02K
- P/E
- -2.70
- P/S
- 0.00
- P/B
- 0.18
- EV/EBITDA
- -5.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -6.94%
- ROIC
- -5.57%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,814,000 · 0.00%
- EPS
- $-0.18 · 0.00%
- Op Income
- $-1,077,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.01
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.69
- Avg Volume
- 0
Get TickerSpark's AI analysis on CURE.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CURE.CN Coverage
We haven't published any research on CURE.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CURE.CN Report →